New shot aims to help overweight people with diabetes control blood sugar
NCT ID NCT06845202
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 33 times
Summary
This study tests a new medicine called ALN-4324 in two groups: first in healthy overweight volunteers to check safety, then in overweight adults with type 2 diabetes to see if it helps control blood sugar. The study is early-stage and focuses on safety and how the drug works in the body. It is not a cure, but aims to improve disease management.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Trial Site
RECRUITINGMontclair, California, 91763, United States
-
Clinical Trial Site
NOT_YET_RECRUITINGWashington D.C., District of Columbia, 20009, United States
-
Clinical Trial Site
RECRUITINGMiami, Florida, 33126, United States
-
Clinical Trial Site
RECRUITINGMarlton, New Jersey, 08053, United States
-
Clinical Trial Site
RECRUITINGMonroe, North Carolina, 28112, United States
-
Clinical Trial Site
RECRUITINGDallas, Texas, 75230, United States
-
Clinical Trial Site
RECRUITINGDallas, Texas, 75246, United States
-
Clinical Trial Site
RECRUITINGBuenos Aires, C1060, Argentina
-
Clinical Trial Site
RECRUITINGBuenos Aires, C1061AAE, Argentina
-
Clinical Trial Site
RECRUITINGBuenos Aires, C1061, Argentina
-
Clinical Trial Site
RECRUITINGSan Miguel de Tucumán, T4000IHE, Argentina
-
Clinical Trial Site
RECRUITINGConcord, L4K 4M2, Canada
-
Clinical Trial Site
RECRUITINGMount Royal, H3P 3P1, Canada
-
Clinical Trial Site
NOT_YET_RECRUITINGVancouver, V5Y 3W2, Canada
-
Clinical Trial Site
NOT_YET_RECRUITINGSantiago, 7500710, Chile
-
Clinical Trial Site
NOT_YET_RECRUITINGSantiago, 7770086, Chile
-
Clinical Trial Site
RECRUITINGSantiago, 8320000, Chile
-
Clinical Trial Site
RECRUITINGEssen, 45355, Germany
-
Clinical Trial Site
RECRUITINGGdansk, 80-546, Poland
-
Clinical Trial Site
NOT_YET_RECRUITINGTarnów, 33-100, Poland
-
Clinical Trial Site
RECRUITINGWarsaw, 02-507, Poland
-
Clinical Trial Site
RECRUITINGWroclaw, 51-162, Poland
Conditions
Explore the condition pages connected to this study.